Back
Early time point in vivo PET/MR is a promising biomarker for determining efficacy of a novel Db(\alphaEGFR)-scTRAIL fusion protein therapy in a colon cancer model
@talk{DivineHKDBASPKP2015, title = {Early time point in vivo PET/MR is a promising biomarker for determining efficacy of a novel Db($\alpha$EGFR)-scTRAIL fusion protein therapy in a colon cancer model}, year = {2015}, slug = {divinehkdbaspkp2015}, author = {Divine, M. R. and Harant, M. and Katiyar, P. and Disselhorst, J. A. and Bukala, D. and Aidone, S. and Siegemund, M. and Pfizenmaier, K. and Kontermann, R. and Pichler, B. J.} }